Increased expression and activity of cathepsin K have been demonstrated in patients, either with mesenchymal tumors or epithelial neoplasms, such as bone cancer, prostate cancer [22], breast cancer [23], melanoma [24], colorectal cancer [25], and lung cancer [26]. This evidence concerns the gene CTSK and mesenchymal cell neoplasm.